Management of chordoma and chondrosarcoma with definitive dose-escalated single-fraction spine stereotactic radiosurgery

Sherry, Alexander D.; Maroongroge, Sean; De, Brian; Amini, Behrang; Conley, Anthony P.; Bishop, Andrew J.; Wang, Chenyang; Beckham, Thomas; Tom, Martin; Briere, Tina; Li, Jing; Yeboa, Debra N.; McAleer, Mary Frances; North, Robert; Tatsui, Claudio E.; Rhines, Laurence D.; Ghia, Amol J.

doi:10.1007/s11060-023-04432-1

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Preprint2

Article1

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Spinal chordoma and chondrosarcoma treatment experiences - a 20-year retrospective study from databases of two medical centers

Kuo,

Yeh,

Chang

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Spinal chordoma and chondrosarcoma treatment experiences - a 20-year retrospective study from databases of two medical centers

Kuo,

Yeh,

Chang

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Spinal Chordoma and Chondrosarcoma Treatment Experiences - A 20-Year Retrospective Study from Databases of Two Medical Centers

Kuo,

Yeh,

Chang

et al. 2024

Preprint

View full text Add to dashboard Cite

The research retrospectively analyzed cases of spinal chordoma and chondrosarcoma involving patients who received treatment at the two hospitals between 2001 and 2023. Among the 48 patients studied (39 chordoma and 9 chondrosarcoma cases), the average age was 53.9 ± 15.8 years, with a range of 17 to 86 years. Out of these patients, 43 underwent excision surgery and were categorized based on tumor margin into negative (R0) or microscopically positive (R1) margin (n = 14) and macroscopically positive (R2) margin (n = 29) groups. The mean overall survival (OS) for R0/R1 and R2 groups was 156.5 ± 19.3 and 79.2 ± 11.9 months, respectively (p value = 0.012). The mean progression-free survival (PFS) for R0/R1 and R2 was 112.9 ± 24.4 and 25.5 ± 5.5 months (p value < 0.001). The study showed that regardless of whether patients in the R0/R1 or R2 groups received radiation therapy (RT) or not, there was no significant improvement in OS or PFS. Specifically, the OS and PFS for the RT only group were 75.9 ± 16.6 and 73.3 ± 18.0 months. In conclusion, the recommended treatment approach for spinal chordoma and chondrosarcoma remains en bloc resection surgery with an appropriate margin. Patients who are unsuitable for or decline surgery may find a beneficial disease control rate with traditional external beam photon/proton therapy.

show abstract